5PSQ-025 Real-world effectiveness and safety of evolocumab and alirocumab

BACKGROUND: In our community, alirocumab and evolocumab, first-in-class proprotein convertase subtilisin–kexin type-9 inhibitors (PCSK9-I), have been authorised by the public health system for the treatment of patients with uncontrolled familial hypercholesterolaemia (FH) with LDL-C >130 mg/dL, u...

全面介紹

Na minha lista:
書目詳細資料
發表在:Eur J Hosp Pharm
Main Authors: Torres, P Rovira, Portilla, A Jimenez, Gonzalez, M Ortiz, Estelrich, MM Santandreu, Lobon, A Gomez, Sanchez, O Delgado, Planella, JR Urgeles
格式: Artigo
語言:Inglês
出版: BMJ Group 2018
主題:
Section 5: Patient safety and quality assurance
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535193/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.379
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍